Jaymun Foundation
Supplements, Research, AML Herbal Regimen
|
Peer reviewed journal papers preferred (PubMed) see: Google Scholar Other Resources: NCCAM Clinical Trial Directory, Complimentary Medicine Search Evidence Based CAM, Oregon State University, Sloan Kettering, Creighton University, NCCAM Herbs, HerbMed, Sigma-Aldrich |
|
Apoptosis,
Review,
Epigenetics,
ROS Therapy,
Blood-Brain,
Cell Paths,
Synergisms
Delivery, Dose Logs, Disclaimer , Supply |
Review:
Curcumin: from ancient medicine to current clinical trials.
AML:
2002 Dec Clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia
2004 Mechanisms of proapoptotic properties of curcumin in chronic and acute myeloid leukemia
AntiCancer:
1998 Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells.
2001 Study on circumen-oligonucleotide conjugate as probable anti-cancer agent
2003 Jan Anticancer potential of curcumin: preclinical and clinical studies.
2005 Mar Induction of apoptosis by curcumin and its implications for cancer therapy.
2005 Sep Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
2006 Jul Multiple Molecular Targets in Cancer Chemoprevention by Curcumin
2008 Jul New mechanisms and therapeutic potential of curcumin for colorectal cancer.
2008 Aug Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells.
Operation:
1995 Oct Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]
1997 Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin.
2002 Dec Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation.
2005 Jun Modulatory Effects of Curcumin and Curcumin Analog on Circulatory Lipid Profiles During Nicotine-Induced Toxicity in Wistar Rats
2005 Aug Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
2006 Jan Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.
2007 Molecular targets of curcumin.
2008 Apr Opposing effects of curcuminoids on serum stimulated and unstimulated angiogenic response.
Blood-Brain Barrier:
2007 Apr Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage
2005 Feb Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo
Histone HypoAcetylation: (Histone acetyltransferase (HAT) and histone deacetylase (HDAC))
1999 Sep Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy
2003 Oct Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype.
2005 May Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
2005 Dec Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B
2005 Jan Histone deacetylase inhibitors.
2005 Apr Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
2006 Mar Curcumin is an inhibitor of p300 histone acetylatransferase.
2006 Jan Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
2007 Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
2008 Jul Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
2008 Oct Histone deacetylase inhibitors as novel anticancer therapeutics
Histone "Hyper"Acetylation: (an good effect dampened by Curcumin?)
2008 Jun Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B).
Advocacy:
2005 Jan A Report On Curcumin's Anti-Cancer Effects
2007 Curcumin - developing a following in American hospitals
BioAvailability:
2000 Oct Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma.
2005 Jan Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
2007 Jul Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.
2007 Jan Curcuminoids form reactive glucuronides in vitro.
2007 Aug Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases.
With Radiation:
2007 Radioprotection and radiosensitization by curcumin.
Cystic Fibrosis:
2004 Apr Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects.
2006 May Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network.
Clinical Trials:
2007 Jul Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer.
Other Research and Analysis:
#1 M.D. Anderson FAQ
#2 M.D. Anderson - Natural Standard
#3 Oregon State University: Linus Pauling Institute
#4 Sloan Kettering
#5 NCCAM Herbs
